Study identifies α-MSH as therapeutic candidate for corneal endothelial disease

Findings from a pioneering study in The American Journal of Pathology, published by Elsevier, reveal that administration of the neuropeptide α-melanocyte-stimulating hormone (α-MSH) promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.

Almirall to license Eloxx’s ZKN-013 for rare skin conditions

Share this article Almirall will develop and market the drug candidate for rare dermatological ailments. Credit: JPC-PROD / Shutterstock.com. Almirall has signed an exclusive licence

March 14, 2024

NKX-101 by Nkarta for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

February 8, 2024

LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab – Biotech Investments

EQS-News: Lindis Biotech GmbH / Key word(s): Agreement LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab 19.11.2024 / 10:07 CET/CEST The

November 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.